Cancer Risk in Transgender People

Christel J. M. de Blok; Koen M. A. Dreijerink; Martin den Heijer

doi:10.1016/j.ecl.2019.02.005

Cancer Risk in Transgender People

Research output: Contribution to journal › Review article › Academic › peer-review

Abstract

Gender-affirming hormonal treatment (HT) in transgender people is considered safe in general, but the question regarding (long-term) risk on sex hormone-related cancer remains. Because the risk on certain types of cancer differs between men and women, and some of these differences are attributed to exposure to sex hormones, the cancer risk may be altered in transgender people receiving HT. Although reliable epidemiologic data are sparse, the available data will be discussed in this article. Furthermore, recommendations for cancer screening and prevention will be discussed as well as whether to withdraw HT at time of a cancer diagnosis.

Original language	English
Pages (from-to)	441-452
Number of pages	12
Journal	Endocrinology and metabolism clinics of North America
Volume	48
Issue number	2
DOIs	https://doi.org/10.1016/j.ecl.2019.02.005
Publication status	Published - 1 Jun 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Cancer
Sex differences
Sex hormones
Transgender

Access to Document

10.1016/j.ecl.2019.02.005

Cite this

@article{52a4f604a6e84fc7b9e91803b4568f2d,

title = "Cancer Risk in Transgender People",

abstract = "Gender-affirming hormonal treatment (HT) in transgender people is considered safe in general, but the question regarding (long-term) risk on sex hormone-related cancer remains. Because the risk on certain types of cancer differs between men and women, and some of these differences are attributed to exposure to sex hormones, the cancer risk may be altered in transgender people receiving HT. Although reliable epidemiologic data are sparse, the available data will be discussed in this article. Furthermore, recommendations for cancer screening and prevention will be discussed as well as whether to withdraw HT at time of a cancer diagnosis.",

keywords = "Cancer, Sex differences, Sex hormones, Transgender",

author = "\{de Blok\}, \{Christel J. M.\} and Dreijerink, \{Koen M. A.\} and \{den Heijer\}, Martin",

year = "2019",

month = jun,

day = "1",

doi = "10.1016/j.ecl.2019.02.005",

language = "English",

volume = "48",

pages = "441--452",

journal = "Endocrinology and metabolism clinics of North America",

issn = "0889-8529",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Cancer Risk in Transgender People

AU - de Blok, Christel J. M.

AU - Dreijerink, Koen M. A.

AU - den Heijer, Martin

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Gender-affirming hormonal treatment (HT) in transgender people is considered safe in general, but the question regarding (long-term) risk on sex hormone-related cancer remains. Because the risk on certain types of cancer differs between men and women, and some of these differences are attributed to exposure to sex hormones, the cancer risk may be altered in transgender people receiving HT. Although reliable epidemiologic data are sparse, the available data will be discussed in this article. Furthermore, recommendations for cancer screening and prevention will be discussed as well as whether to withdraw HT at time of a cancer diagnosis.

AB - Gender-affirming hormonal treatment (HT) in transgender people is considered safe in general, but the question regarding (long-term) risk on sex hormone-related cancer remains. Because the risk on certain types of cancer differs between men and women, and some of these differences are attributed to exposure to sex hormones, the cancer risk may be altered in transgender people receiving HT. Although reliable epidemiologic data are sparse, the available data will be discussed in this article. Furthermore, recommendations for cancer screening and prevention will be discussed as well as whether to withdraw HT at time of a cancer diagnosis.

KW - Cancer

KW - Sex differences

KW - Sex hormones

KW - Transgender

UR - https://www.scopus.com/pages/publications/85063279421

U2 - 10.1016/j.ecl.2019.02.005

DO - 10.1016/j.ecl.2019.02.005

M3 - Review article

C2 - 31027551

SN - 0889-8529

VL - 48

SP - 441

EP - 452

JO - Endocrinology and metabolism clinics of North America

JF - Endocrinology and metabolism clinics of North America

IS - 2

ER -

Cancer Risk in Transgender People

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this